Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4260-4271

  Benjamin, John M ^a   Moore, Brioni R ^a,b   Salman, Sam ^b   Page Sharp, Madhu ^c,d   Tawat, Somoyang ^a   Yadi, Gumal ^a   Lorry, Lina ^a   Siba, Peter M ^b,e   Batty, Kevin T ^c,d   Robinson, Leanne J ^a,f,g   Mueller, Ivo ^e,g,h   Davis, Timothy M E ^b  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e JAMES COOK UNIVERSITY   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Centre de Recerca en Salut Internacional de Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; FAT INTAKE; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE PAIN; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FAT INTAKE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIQUID CHROMATOGRAPHY; MALARIA; MASS SPECTROMETRY; PARASITEMIA; PLASMODIUM FALCIPARUM; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; QT INTERVAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RASH; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; STILLBIRTH; THIRD TRIMESTER PREGNANCY; VOMITING; ADOLESCENT; BIOAVAILABILITY; DRUG COMBINATION; EPIDEMIOLOGY; FOOD DRUG INTERACTION; MALARIA, FALCIPARUM; METABOLISM; NEWBORN; PAPUA NEW GUINEA; PREGNANCY; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; BIOLOGICAL AVAILABILITY; DIETARY FATS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FOOD-DRUG INTERACTIONS; HUMANS; INFANT, NEWBORN; MALARIA, FALCIPARUM; MODELS, STATISTICAL; PAPUA NEW GUINEA; PREGNANCY; PREGNANCY OUTCOME; PYRIMETHAMINE; QUINOLINES; SULFADOXINE; YOUNG ADULT;

EID: 84935875457     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00326-15     Document Type: Article

References (60)

1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. 2007. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7:93-104. http://dx.doi.org/10.1016/S1473-3099(07)70021-X.
2. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG. 1996. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 55:33-41.
3. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, Duffy PE. 2005. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Med 2:e407. http://dx.doi.org/10.1371 /journal.pmed.0020407.
4. Davis TM, Mueller I, Rogerson SJ. 2010. Prevention and treatment of malaria in pregnancy. Future Microbiol 5:1599-1613. http://dx.doi.org/10.2217/fmb.10.113.
5. nd ed. World Health Organization, Geneva, Switzerland.
6. World Health Organization. 2007. Technical expert group meeting on intermittent preventive treatment in pregnancy (IPTp). World Health Organization, Geneva, Switzerland.
7. World Health Organization Global Malaria Programme. 2012. Updated WHO policy recommendation (October 2012): intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). World Health Organization, Geneva, Switzerland.
8. Gosling RD. 2010. Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8:589-606. http://dx.doi.org/10.1586/eri.10.36.
9. van Vugt M, van Beest A, Sicuri E, van Tulder M, Grobusch MP. 2011. Malaria treatment and prophylaxis in endemic and nonendemic countries: evidence on strategies and their cost-effectiveness. Future Microbiol 6:1485-1500. http://dx.doi.org/10.2217/fmb.11.138.
10. Moussiliou A, De Tove YS-S, Doritchamou J, Luty AJF, Massougbodji A, Alifrangis M, Deloron P, Ndam NT. 2013. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J 12:195. http://dx.doi.org/10.1186/1475-2875-12-195.
11. Chico RM, Pittrof R, Greenwood B, Chandramohan D. 2008. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar J 7:255. http://dx.doi.org/10.1186/1475-2875-7-255.
12. Adam I, Tarning J, Lindegardh N, Mahgoub H, McGready R, Nosten FH. 2012. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 87:35-40. http://dx.doi.org/10.4269/ajtmh.2012.11-0410.
13. Hoglund RM, Adam I, Hanpithakpong W, Ashton M, Lindegardh N, Day NP, White NJ, Nosten F, Tarning J. 2012. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 11:398. http://dx.doi.org/10.1186/1475-2875-11-398.
14. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N. 2012. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 56:1997-2007. http://dx.doi.org/10.1128/AAC.05756-11.
15. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS, Robinson LJ, Rosanas-Urgell A, Wapling J, Lufele E, Kongs C, Samol P, Sui D, Singirok D, Bardaji A, Schofield L, Menendez C, Betuela I, Siba P, Mueller I, Rogerson SJ. 2015. Sulphadoxinepyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. BMC Med 13:9. http://dx.doi.org/10.1186/s12916-014-0258-3.
16. Mueller I, Rogerson S, Mola GD, Reeder JC. 2008. A review of the current state of malaria among pregnant women in Papua New Guinea. P N G Med J 51:12-16.
17. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, MacArthur JR, Luntamo M, Ashorn P, Doumbo OK, ter Kuile FO. 2013. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 309:594-604. http://dx.doi.org/10.1001/jama.2012.216231.
18. Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI. 2010. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther 87:226-234. http://dx.doi.org/10.1038/clpt.2009.177.
19. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM. 2009. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother 53:4368-4376. http://dx.doi.org/10.1128/AAC.00335-09.
20. Koleala T, Karl S, Laman M, Moore BR, Benjamin J, Barnadas C, Robinson LJ, Kattenberg JH, Javati S, Wong RPM, Rosanas-Urgell A, Betuela I, Siba PM, Mueller I, Davis TME. 2015. Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malaria J 14:37. http://dx.doi.org/10.1186/s12936-015-0560-3.
21. Barnadas C, Senn N, Iga J, Timinao L, Javati S, Malau E, Rarau P, Reeder JC, Siba P, Karunajeewa H, Zimmerman PA, Davis TM, Mueller I. 2014. Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea. Antimicrob Agents Chemother 58:6958-6961. http://dx.doi.org/10.1128/AAC.03323-14.
22. Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D, Rogerson S, Nosten F. 2012. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12:75-88. http://dx.doi.org/10.1016/S1473-3099(11)70315-2.
23. Batty KT, Moore BR, Stirling V, Ilett KF, Page-Sharp M, Shilkin KB, Mueller I, Rogerson SJ, Karunajeewa HA, Davis TM. 2010. Investigation of reproductive toxicity of piperaquine in mice. Reprod Toxicol 29:206-213. http://dx.doi.org/10.1016/j.reprotox.2009.10.013.
24. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87. http://dx.doi.org/10.2165/00003495-200565010-00004.
25. Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. 2013. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 10:CD008492. http://dx.doi.org/10.1002/14651858.CDC008492.pub3.
26. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. 2014. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 1:CD010927. http://dx.doi.org /10.1002/14651858.CDD010927.
27. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J, Laochan N, Than HH, Mu O, Win AK, Singhasivanon P, White N, Nosten F. 2011. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 55:5500-5506. http://dx.doi.org/10.1128/AAC.05067-11.
28. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Sugiarto P, Tjitra E, Anstey NM, Price RN. 2014. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One 9:e84976. http://dx.doi.org/10.1371/journal.pone.0084976.
29. White NJ. 2005. Intermittent presumptive treatment for malaria. PLoS Med 2:e3. http://dx.doi.org/10.1371/journal.pmed.0020003.
30. Cisse B, Cairns M, Faye E, O ND, Faye B, Cames C, Cheng Y, M ND, Lo AC, Simondon K, Trape JF, Faye O, JL ND, Gaye O, Greenwood B, Milligan P. 2009. Randomized trial of piperaquine with sulfadoxinepyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 4:e7164. http://dx.doi.org/10.1371/journal.pone.0007164.
31. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM. 2010. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob Agents Chemother 54:1186-1192. http://dx.doi.org/10.1128/AAC.01269-09.
32. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman PA, Reeder JC, Beeson JG, Schofield L, King CL, Mueller I. 2007. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 76:997-1008.
33. Laman M, Moore BR, Benjamin J, Padapu N, Tarongka N, Siba P, Betuela I, Mueller I, Robinson LJ, Davis TM. 2014. Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malar J 13:145. http://dx.doi.org/10.1186/1475-2875-13-145.
34. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TM. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 52:237-243. http://dx.doi.org/10.1128/AAC.00555-07.
35. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, Mueller I, Davis TME. 2011. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 55:5306-5313. http://dx.doi.org/10.1128/AAC.05136-11.
36. Beal S, Sheiner LB. 1980. NONMEM users guide part I. Division of Clinical Pharmacology, University of California, San Fransisco, San Francisco, CA.
37. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25-36. http://dx.doi.org/10.2133/dmpk.24.25.
38. Upton RN. 2004. Calculating the hybrid (macro) rate constants of a threecompartment mamillary pharmacokinetic model from known micro-rate constants. J Pharmacol Toxicol Methods 49:65-68. http://dx.doi.org/10.1016/j.vascn.2003.09.001.
39. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, Siba P, Ilett KF, Mueller I, Davis TME. 2012. A pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 56:3288-3297. http://dx.doi.org/10.1128/AAC.06232-11.
40. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726. http://dx.doi.org/10.1007/s10928-007-9066-0.
41. Lee SH, Chen SA, Wu TJ, Chiang CE, Cheng CC, Tai CT, Chiou CW, Ueng KC, Chang MS. 1995. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 76: 675-678. http://dx.doi.org/10.1016/S0002-9149(99)80195-7.
42. Tawam M, Levine J, Mendelson M, Goldberger J, Dyer A, Kadish A. 1993. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 72:838-840. http://dx.doi.org/10.1016/0002-9149(93)91078-V.
43. Baker DA. 2010. Malaria gametocytogenesis. Mol Biochem Parasitol 172: 57-65. http://dx.doi.org/10.1016/j.molbiopara.2010.03.019.
44. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F. 2009. Safety and efficacy of dihydroartemisininpiperaquine in falciparum malaria: A prospective multi-centre individual patient data analysis. PLoS One 4:e6358. http://dx.doi.org/10.1371/journal.pone.0006358.
45. Jimmy S, Kemiki AD, Vince JD. 2003. Neonatal outcome at Modilon Hospital, Madang: a 5-year review. P N G Med J 46:8-15.
46. Roshammar D, Hai TN, Hietala SF, Huong NV, Ashton M. 2006. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol 62:335-341. http://dx.doi.org/10.1007/s00228-005-0084-9.
47. Annerberg A, Lwin KM, Lindegardh N, Khrutsawadchai S, Ashley E, Day NJP, Singhasivanon P, Tarning J, White NJ, Nosten F. 2011. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother 55:3971-3976. http://dx.doi.org/10.1128/AAC.00279-11.
48. Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, Page-Sharp M, Robinson LJ, Siba P, Batty KT, Mueller I, Davis TM. 2014. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 58:5784-5794. http://dx.doi.org/10.1128/AAC.03314-14.
49. Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NP. 2014. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother 58: 2052-2058. http://dx.doi.org/10.1128/AAC.02318-13.
50. Hai TN, Hietala SF, van Huong N, Ashton M. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop 107:145-149. http://dx.doi.org/10.1016/j.actatropica.2008.05.013.
51. Nguyen TC, Nguyen NQ, Nguyen XT, Bui D, Travers T, Edstein MD. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg 79:620-623.
52. Sim I-K, Davis TME, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 49:2407-2411. http://dx.doi.org/10.1128/AAC.49.6.2407-2411.2005.
53. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 44:989-1008. http://dx.doi.org/10.2165/00003088-200544100-00001.
54. Little BB. 1999. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 93:858-868. http://dx.doi.org/10.1016/S0029-7844(98)00444-X.
55. Edwards G, Looareesuwan S, Davies AJ, Wattanagoon Y, Phillips RE, Warrell DA. 1988. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol 25:477-485. http://dx.doi.org/10.1111/j.1365-2125.1988.tb03332.x.
56. Reuter SE, Upton RN, Evans AM, Navaratnam V, Olliaro PL. 2015. Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 70:868-876. http://dx.doi.org/10.1093/jac/dku430.
57. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M. 2009. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 9:760-774. http://dx.doi.org/10.1016/S1473-3099(09)70320-2.
58. McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F. 2006. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 62:367-371. http://dx.doi.org/10.1007/s00228-006-0118-y.
59. Morris CA, Onyamboko MA, Capparelli E, Koch MA, Atibu J, Lokomba V, Douoguih M, Hemingway-Foday J, Wesche D, Ryder RW, Bose C, Wright L, Tshefu AK, Meshnick S, Fleckenstein L. 2011. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 10:114. http: //dx.doi.org/10.1186/1475-2875-10-114.
60. Teo A, Hasang W, Randall LM, Feng G, Bell L, Unger H, Langer C, Beeson JG, Siba PM, Mueller I, Molyneux ME, Brown GV, Rogerson SJ. 2014. Decreasing malaria prevalence and its potential consequences for immunity in pregnant women. J Infect Dis 210:1444 -1455. http://dx.doi.org/10.1093/infdis/jiu264.